4,419 results on '"Stanley, R. A."'
Search Results
2. Contributors
3. Managing steam quality in food and beverage processing
4. Racial and Ethnic Inequality in Latin America
5. Algorithm Enhancements for Improvement of Localized Classification of Uterine Cervical Cancer Digital Histology Images
6. AB0211 THE IMPACT OF INFLAMMATORY ARTHRITIS ON EMPLOYMENT PATTERNS IN THE WEST OF IRELAND
7. Improved clinical trial race/ethnicity reporting and updated inclusion profile, 2017–2022: A New Jersey snapshot
8. In situ exsolution of ceria nanoparticles in perovskite cathode for elevating CO2 reduction performance of solid oxide electrolysis cells (SOECs)
9. Enhancing Electrochemical Efficiency of Solid Oxide Electrolysis Cells for Carbon Dioxide Reduction Through Nickel‐Doped Titanate‐Based Cathode with Doped Ceria Electrolyte
10. Indigenous-Led, Community-Based Language Reclamation and Regeneration Initiatives
11. Impact of Government Programs on Soybean Production, Trade and Policies
12. Scholar, Entrepreneur, and Editorial Innovator
13. NATO's inherent dilemma: strategic imperatives vs. value foundations
14. Supplementary Figures 1 from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
15. Supplementary tables 1 from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
16. Data from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
17. Supplementary tables 1 from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
18. Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
19. Data from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
20. Supplementary Figures 1 from Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
21. Ultra-fast degradation of thiazine dyes in the presence of natural sunlight by coupling of titania with zinc oxide nanoparticles in the room temperature
22. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
23. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
24. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy
25. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
26. IL15 (N-803) and IL21 (oHSV-21) Significantly Enhance ROR1 CAR NK Cells Against Pediatric Neuroblastoma
27. Fusion of Deep Learning with Conventional Imaging Processing: Does It Bring Artificial Intelligence Closer to the Clinic?
28. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks
29. Parental gender affirmation model: A cultural informed framework
30. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
31. CAR T Cell Therapy
32. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies
33. Breast Cancer: Surgical Perspectives
34. Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up
35. Tipologia de Municípios Produtores de Bovinos de Corte no Bioma Amazônia a partir do Censo Agropecuário 2017
36. Diferenciação e caracterização de municípios produtores de bovinos de corte do Bioma Pampa segundo o Censo Agropecuário 2017
37. A computational modeling apprssoach for prediction of polarization losses inside porous micro-structured cathode used for CO2 reduction in SOEC
38. A Scientist’s Personal 70-Year Discourse with Past, Present and Future Coastal Change
39. Acetazolamide
40. Lorazepam
41. Assessing the Effectiveness of Treatment
42. Retinoids in Leukemia and Myelodysplastic Syndromes
43. Current Concepts of Implantation and Decidualization
44. Laboratory Responses of Whole Organisms Exposed to Pulp and Paper Mill Effluents: 1991–1994
45. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma
46. Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma
47. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
48. POSTERIOR TIBIAL NERVE STIMULATION WITH VERSUS WITHOUT MIRABEGRON IN WOMEN WITH REFRACTORY UUI AND OAB-WET: A RANDOMIZED CONTROLLED TRIAL
49. High-sensitivity electronic Stark spectrometer featuring a laser-driven light source
50. Compassion-Focused Therapy to Reduce Body Weight Shame for Individuals With Obesity: A Randomized Controlled Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.